Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ErbB2 Positive Metastatic Breast Cancer

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Chang-Fang Chiu, China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01658358
First received: August 1, 2012
Last updated: February 26, 2013
Last verified: February 2013

August 1, 2012
February 26, 2013
July 2012
September 2014   (final data collection date for primary outcome measure)
Phase I part recommended dose of the combination of lapatinib with Lipo-Dox [ Time Frame: Phase I: 6 months ] [ Designated as safety issue: No ]
-Phase I part: To determine the recommended dose of the combination of lapatinib with Lipo-Dox
Same as current
Complete list of historical versions of study NCT01658358 on ClinicalTrials.gov Archive Site
Objective Response Rate [ Time Frame: Phase II: 12 months ] [ Designated as safety issue: No ]
-Phase II part: To determined the objective response rate
Same as current
Not Provided
Not Provided
 
ErbB2 Positive Metastatic Breast Cancer
A Phase I/II Study of Lapatinib (Tykerb) Plus Liposomal Doxorubicin Hydrochloride ( Lipo-Dox) for Patients With ErbB2 Positive Metastatic Breast Cancer

Objectives:

Phase I part

  • Primary Objective: To determine the recommended dose of the combination of lapatinib with Lipo-Dox as first line chemotherapy in patients with ErbB2 positive metastatic breast cancer.
  • Secondary Objectives:To define the safety profile; To observe the response rate and progression free survival

Phase II part

  • Primary Objective :To determined the objective response rate of the combination of lapatinib with Lipo-Dox as first line chemotherapy in patients with ErbB2 positive metastatic breast cancer.
  • Secondary Objectives:To define the safety profile; To determined the progression free survival

In phase I part Lapatinib (L) - dose level I, II 1000mg po daily dose level III, IV 1250mg po daily Intravenous Lipo Dox at the dose level reached on days 1 of a 21 days cycle• The recommended duration of combination treatment for each patient is at least 8 cycles, then, with continue combination treatment cycles or single lapatinib treatment (start with 1500 mg per day) at investigator's discretion. The treatment will stop if progressive disease, unacceptable toxicity or patient's refusal occurred. Intra patient escalation of dose level is allowed if no major toxicity noted.

In phase II part Patients will receive recommended dose according to phase I study result. The recommended duration of combination treatment for each patient is at least 8 cycles, then, with continue combination treatment cycles or single lapatinib treatment (start with 1500 mg per day) at investigator's discretion. The treatment will stop if progressive disease, unacceptable toxicity or patient's refusal occurred. Intra patient escalation of dose level is allowed if no major toxicity noted.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Metastatic Breast Cancer
  • Drug: Lapatinib
    • dose level I, II 1000mg po daily
    • dose level III, IV 1250mg po daily
    Other Name: Tykerb
  • Drug: Lipo-Dox
    at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
    Other Name: Liposomal doxorubicin hydrochloride
  • Experimental: Phase I part :Systemic Therapy
    • Drug: Lapatinib
    • Drug: Lipo-Dox
    Interventions:
    • Drug: Lapatinib
    • Drug: Lipo-Dox
  • Experimental: Phase II part
    • Drug: Lapatinib
    • Drug: Lipo-Dox Patients will receive recommended dose according to phase I study result. at least 8 cycles, then, with continue combination treatment cycles or single lapatinib treatment (start with 1500 mg per day) at investigator's discretion.
    Interventions:
    • Drug: Lapatinib
    • Drug: Lipo-Dox
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
15
September 2014
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the breast with evidence of metastatic disease
  • Documented ErbB2 over expression or amplified disease in the invasive component of the primary or metastatic lesion as defined by:
  • ErbB2 gene amplification by FISH(>6 ErbB2 gene copies per nucleus, or a FISH ratio (ErbB2 gene copies to chromosome 17 signals) of >than 2.2;
  • Measurable disease, defined as ≥1 lesion that can be accurately measured in ≥1 dimension as ≥20 mm by conventional techniques OR as ≥10 mm by spiral CT scan
  • In phase II part, patients must be chemo-naïve in metastatic setting.
  • In phase I part, patient may have received prior chemotherapy in metastatic setting.
  • In both phase I and II part, prior Anthracyclines allowed provided total dose of doxorubicin hydrochloride ≤240 mg/m² or epirubicin ≤ 600 mg/m².
  • At least 6 months since prior Anthracyclines, and 6 weeks since prior Taxane.
  • Patient must be informed and well understand that in current standard of treatment, suggested first line treatments for erbB-2 positive, visceral organ metastatic breast cancer are combination of chemotherapy with herceptin.
  • In phase II part, patient must not have exposed to ant-erbB2 targeted therapy treatment in metastatic setting. Herceptin treatment in the neoadjuvant or adjuvant setting is permitted provide that at least 12 months has elapsed since the last dose of herceptin therapy.
  • In phase I part, patient may have received prior anti-erbB-2 targeted treatment in metastatic setting.
  • Hormone receptor and menopausal status are not specified. Prior treatment with endocrine therapy in the adjuvant or metastatic setting is permitted provided that therapy be discontinued.
  • Prior treatments with radiation therapy for palliative management of non-target lesion metastatic disease is permitted provided that at least 2 weeks have elapsed since the last fraction of radiation therapy, disease progression has been documented and all treatment related adverse events are ≦ grade 1 at the time of registration.
  • Life expectancy ≥ 12 weeks
  • ECOG performance status 0-1
  • Patients must have normal organ and marrow function measured within 14 days prior to study entry as defined below:
  • WBC ≥ 3,000/mm3
  • Absolute neutrophil count ≥ 1,500/mm3
  • Platelet count ≥ 100,000/mm3
  • Bilirubin normal
  • AST/ALT ≤ 2.5 times upper limit of normal
  • Normal serum creatinine OR creatinine clearance ≥60 mL/min
  • LVEF ≥ 50% (by MUGA)
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Able to swallow and retain medication
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
  • Patient consent must be obtained.

Exclusion Criteria:

  • Pregnant or lactating women.
  • Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
  • Prior therapy with concurrent use of Lapatinib.
  • CNS metastasis.
  • Ongoing other concurrent investigational agents or anticancer therapy
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, serious non-healing wound/ulcer/bone fracture, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patients with GI tract disease resulting in an inability to take medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).
Female
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
NCT01658358
EGF114081
No
Chang-Fang Chiu, China Medical University Hospital
China Medical University Hospital
Not Provided
Principal Investigator: Chang-Fang Chiu, PhD China Medical University Hospital
China Medical University Hospital
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP